Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
47.24
+1.22 (2.65%)
Mar 6, 2026, 10:26 AM EST - Market open

KNSA Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
677.56423.24270.26220.1838.54
Revenue Growth (YoY)
60.09%56.61%22.75%471.24%-
Cost of Revenue
77.6760.9133.4122.99.1
Gross Profit
599.89362.33236.85197.2929.44
Selling, General & Admin
196.27168.01129.4397.9585.95
Research & Development
96.85111.6276.165.4999.3
Other Operating Expenses
229.55128.3156.5224.070.84
Total Operating Expenses
522.67407.95262.05187.51186.08
Operating Income
77.22-45.62-25.29.77-156.64
Total Non-Operating Income (Expense)
11.659.468.541.250.1
Pretax Income
88.87-36.15-16.6511.03-156.54
Provision for Income Taxes
-29.86-7.0430.74172.34-1.39
Net Income
59.01-43.1914.08183.36-157.92
Net Income to Common
59.01-43.1914.08183.36-157.92
Net Income Growth
---92.32%--
Shares Outstanding (Basic)
7471706969
Shares Outstanding (Diluted)
7971727069
Shares Change (YoY)
10.58%-0.69%2.13%2.69%10.89%
EPS (Basic)
0.80-0.600.202.64-2.30
EPS (Diluted)
0.75-0.600.202.60-2.30
EPS Growth
---92.31%--
Free Cash Flow
136.4225.4113.175.7-126.71
Free Cash Flow Growth
436.82%92.94%130.99%--
Free Cash Flow Per Share
1.730.360.180.08-1.85
Gross Margin
88.54%85.61%87.64%89.60%76.39%
Operating Margin
11.40%-10.78%-9.32%4.44%-406.38%
Profit Margin
8.71%-10.21%5.21%83.28%-409.72%
FCF Margin
20.13%6.00%4.87%2.59%-328.75%
EBITDA
78.78-43.92-22.8612.18-154.28
EBITDA Margin
11.63%-10.38%-8.46%5.53%-400.27%
EBIT
77.22-45.62-25.29.77-156.64
EBIT Margin
11.40%-10.78%-9.32%4.44%-406.38%
Effective Tax Rate
-33.60%19.48%-184.58%1563.01%0.88%
Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q